A phase 3 study (NCT04822181), which enrolled 1200 patients with biopsy-proven MASH and fibrosis, is currently ongoing to assess the benefit of OW subcutaneous semaglutide 2 mg in this setting 93
These cases were usually linked to dehydration, vomiting, or diarrhea common side effects of Semaglutide that can reduce fluid levels in the body
(Source: KFF, January 2026) Even Where Covered, Utilization Controls Limit Access When state Medicaid programs do cover GLP-1s, coverage is typically subject to prior authorization and other utilization controls that further restrict access in practice
Citations Citations to this article as recorded by Comparative Analysis of Clinical Outcomes in Patients With Type 2 Diabetes Mellitus on Monotherapy Versus Combination Therapy Hariballav Mahapatra, Piyush Kumar Gupta, Ajo Paul, Amit Nampalliwar, Manju Bansal, Baijnath Das, K